An atypical femoral fracture: case report
DOI:
https://doi.org/10.32385/rpmgf.v39i1.13298Keywords:
Osteoporosis, Bisphosphonates, Femoral factures, Case reportAbstract
Introduction: Osteoporosis is the most common metabolic disease of bone. Bisphosphonates are the first-line pharmacological class used in its treatment. Despite its effectiveness in reducing the risk of osteoporotic fractures, reports of atypical femur fractures have emerged as potential complications of long-term treatment with these drugs.
Case report: We present the case of a 78-year-old patient, medicated for 13 years with alendronic acid 70mg + cholecalciferol 2800 IU, weekly, transported to the orthopedics emergency service following a low-energy trauma, resulting in a subtrochanteric fracture of the left femur.
Conclusion: There is yet no established causal relationship between the occurrence of atypical femur fractures and prolonged treatment with bisphosphonates. However, this association should not be ignored, and it is essential to assess the risks and benefits before starting treatment, as well as to promote active surveillance of patients under long-term bisphosphonate therapy. Studies report that at least half of patients who suffer atypical fractures of the femur present prodromes of pain in the thigh or groin, which occurred in the case reported. Therefore, these symptoms should be valued and actively questioned, especially in patients receiving bisphosphonates. Regardless of this potential risk, bisphosphonates remain the first-line drugs for the prevention of osteoporotic fractures and the duration of treatment must be individualized.
Downloads
References
Giordano V, Lages MM, Santana E, Souza FS, Albuquerque RP, Amaral NP. Fraturas femorais atípicas por uso prolongado de bifosfonatos: mitos e verdades [Atypical femoral fractures by prolonged use of bisphosphonates: myths and truths]. J Bras Med. 2013;101(2):13-8. Portuguese
Sahin K, Ergin ON, Bayram S, Akgül T. Atypical femoral fractures related to bisphosphonate use: a comprehensive review of 19 patients. Ulus Travma Acil Cerrahi Derg. 2019;25(6):603-10.
Black JD, Kancherla VK, De Long Jr WG. A review of atypical femoral fractures from a tertiary care teaching hospital: an alarming trend? J Orthop Trauma. 2016;30(4):182-8.
Figueiredo MP, Pato M, Pereira C, Amaral F, Felicíssimo P. Associação entre fraturas atípicas do fémur e o uso de bifosfonatos: revisão da literatura [The association between atypical femoral fractures and biphosphonates: review of the literature]. Rev Clin Hosp Prof Dr Fernando Fonseca. 2016;4(1-2):32-40. Portuguese
Lim SJ, Yeo I, Yoon PW, Yoo JJ, Rhyu KH, Han SB, et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. Osteoporos Int. 2018;29(11):2427-35.
Méndez-Gil A, Prat-Fabregat S, Domingo-Trepat A, Navarro-López M, Camacho-Carrasco P, Carreño-Delgado A, et al. ¿Qué sabemos de las fracturas atípicas en los pacientes en tratamiento con bifosfonatos? Revisión bibliográfica a raíz de una serie de casos [What do we know about atypical fractures in patients on biphosphonates treatment? A literature review using a case series]. Rev Esp Cir Ortop Traumatol. 2013;57(2):95-105. Spanish
Zheng N, Tang N, Qin L. Atypical femoral fractures and current management. J Orthop Translat. 2016;7:7-22.
Koh A, Guerado E, Giannoudis PV. Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J. 2017;99-B(3):295-302.
Lian K, Trollip J, Sandhu S, Moosavi M, Gill A, Kendler D, et al. Audit of atypical femoral fractures and a description of some of their features. Can Assoc Radiol J. 2016;67(1):69-75.
Dandinoglu T, Akarsu S, Karadeniz M, Tekin L, Anbal S, Kiralp MZ. Can long-term bisphosphonate use causes low-energy fractures? A case report. Osteoporos Int. 2014;25(2):773-6.
Clout A, Narayanasamy N, Harris I. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy. J Orthop Surg. 2016;24(1):36-40.
Leclerc JT, Michou L, Vaillancourt F, Pelet S, Simonyan D, Belzile EL. Prevalence and characteristics of atypical periprosthetic femoral fractures. J Bone Miner Res. 2019;34(1):83-92.
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.
Im GI, Jeong SH. Pathogenesis, management and prevention of atypical femoral fractures. J Bone Metab. 2015;22(1):1-8.
MacKenzie SA, Ng RT, Snowden G, Powell-Bowns MF, Duckworth AD, Scott CE. Periprosthetic atypical femoral fractures exist and are associated with duration of bisphosphonate therapy. Bone Joint J. 2019;101-B(10):1285-91.
Adler RA. Bisphosphonates and atypical femoral fractures. Curr Opin Endocrinol Diabetes Obes. 2016;23(6):430-4.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Portuguese Journal of Family Medicine and General Practice
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
